Trump signs executive order on psychedelic drug research
An executive order aims to expedite research and approval processes for psychedelic therapies. The focus includes treatments for conditions such as PTSD. (sources: abcnews, nbcnews, usatoday, cbsnews, pbs)
Trump signed an executive order to accelerate the research and approval of psychedelic-based therapies. This includes drugs like ibogaine, which has gained attention from various groups.
- The executive order targets the acceleration of research into psychedelic therapies.
- Conditions such as PTSD are highlighted as potential areas for treatment.
- Ibogaine is specifically mentioned as a drug of interest in the order.
Why it matters
The order reflects a growing interest in alternative treatments for mental health conditions.
↓ Why this is on ModernAction
2 bills on this issue are moving right now — and the most active one is Freedom to Heal Act of 2025.
HR6434 · 119th Congress
Freedom to Heal Act of 2025
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What HR6434 actually does
This story is about Trump signs executive order accelerating research into psychedelic drug therapies. This bill would create a special registration process for physicians to directly administer Schedule I eligible investigational drugs to.
If passed, it would:
- Create a special registration process for physicians to directly administer Schedule I eligible investigational drugs • Set timelines/requirements for the Attorney General (DEA) to act on applications and allow electronic submissions.
1 other bill moving on this issue
Take action on any of them individually.
This story is about Trump signs executive order accelerating research into psychedelic drug therapies. This bill would require VA to designate “innovative therapies centers of excellence” and report findings/recommendations.
If passed, it would
- Require VA to designate “innovative therapies centers of excellence” and report findings/recommendations • Define “innovative therapy” to include MDMA, 5-MeO-DMT, ibogaine, ketamine, and psilocybin; authorize appropriations.
Top coverage · 10 sources